Biotech Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Northwest Biotherapeutics, Inc.
CXCR-4 clinical antibodies identified
July 30th, 2003
Northwest Biotherapeutics, Inc., (NWBT) announced the completion of its in-vitro preclinical assessment of a battery of proprietary monoclonal antibodies directed against the cancer associated target CXCR-4. Two of the studied antibodies inhibited tumor cell division and exhibited other anticancer properties. NWBT scientists were the first to discover that CXCR-4 is over-expressed in cancer. The original findings showed CXCR-4 detectable in glioblastoma and breast cancer tissue but not measurable in normal counterpart tissue. These findings formed the basis for company patent applications filed in early 1998. Subsequently, CXCR-4 has been identified...
Source: Biotech Week (2003-07-30)
|
